Seer Reported PrognomiQ Completes Largest And Deepest Unbiased Mass Spectrometry Plasma Biomarker Study Using Seer Proteograph And Thermo Fisher Orbitrap Astral Mass Spectrometer
Portfolio Pulse from Charles Gross
PrognomiQ has completed the largest and deepest unbiased mass spectrometry plasma biomarker study using Seer Proteograph and Thermo Fisher Orbitrap Astral Mass Spectrometer.
June 02, 2024 | 3:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PrognomiQ's use of Seer Proteograph in the largest unbiased mass spectrometry plasma biomarker study highlights the effectiveness and potential of Seer's technology.
The successful completion of a significant study using Seer's technology is likely to boost investor confidence and highlight the company's capabilities in the biotech sector.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Thermo Fisher's Orbitrap Astral Mass Spectrometer was used in PrognomiQ's largest unbiased mass spectrometry plasma biomarker study, underscoring the instrument's importance in advanced research.
The use of Thermo Fisher's mass spectrometer in a major study highlights the instrument's capabilities and could positively impact the company's reputation and sales in the biotech research market.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70